0001209191-20-028801.txt : 20200513 0001209191-20-028801.hdr.sgml : 20200513 20200513162043 ACCESSION NUMBER: 0001209191-20-028801 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200511 FILED AS OF DATE: 20200513 DATE AS OF CHANGE: 20200513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sachdev Amit CENTRAL INDEX KEY: 0001406338 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20873434 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-11 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001406338 Sachdev Amit C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Patient Officer Common Stock 2020-05-11 4 M 0 10665 131.89 A 45768 D Common Stock 2020-05-11 4 S 0 800 276.25 D 44968 D Common Stock 2020-05-11 4 S 0 201 277.38 D 44767 D Common Stock 2020-05-11 4 S 0 655 279.67 D 44112 D Common Stock 2020-05-11 4 S 0 1817 280.77 D 42295 D Common Stock 2020-05-11 4 S 0 1398 281.74 D 40897 D Common Stock 2020-05-11 4 S 0 913 282.89 D 39984 D Common Stock 2020-05-11 4 S 0 1100 283.98 D 38884 D Common Stock 2020-05-11 4 S 0 2314 285.15 D 36570 D Common Stock 2020-05-11 4 S 0 1367 285.94 D 35203 D Common Stock 2020-05-11 4 S 0 100 286.72 D 35103 D Common Stock 882 I 401(k) Common Stock 14002 I GRAT Stock Option (Right to Buy) 131.89 2020-05-11 4 M 0 10665 0.00 D 2025-07-20 Common Stock 10665 0 D Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $276.25 (range $275.73 to $276.52). Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $277.38 (range $277.26 to $277.50). Open market sales reported on this line occurred at a weighted average price of $279.67 (range $279.21 to $280.05). Open market sales reported on this line occurred at a weighted average price of $280.77 (range $280.33 to $281.26). Open market sales reported on this line occurred at a weighted average price of $281.74 (range $281.33 to $282.29). Open market sales reported on this line occurred at a weighted average price of $282.89 (range $282.44 to $283.24). Open market sales reported on this line occurred at a weighted average price of $283.98 (range $283.57 to $284.44). Open market sales reported on this line occurred at a weighted average price of $285.15 (range $284.57 to $285.55). Open market sales reported on this line occurred at a weighted average price of $285.94 (range $285.63 to $286.59). Fully vested. /s/ Sabrina Yohai, Attorney-in-Fact 2020-05-13